CN111065387B - 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 - Google Patents

肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 Download PDF

Info

Publication number
CN111065387B
CN111065387B CN201880058214.0A CN201880058214A CN111065387B CN 111065387 B CN111065387 B CN 111065387B CN 201880058214 A CN201880058214 A CN 201880058214A CN 111065387 B CN111065387 B CN 111065387B
Authority
CN
China
Prior art keywords
polysaccharide
carrier protein
protein conjugate
conjugate
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880058214.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111065387A (zh
Inventor
R·J·波拉姆博
C·阿拜古纳瓦达纳
L·K·穆塞
M·J·科辛斯基
Y·A·崔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme BV
Priority to CN202311033166.9A priority Critical patent/CN117018172A/zh
Publication of CN111065387A publication Critical patent/CN111065387A/zh
Application granted granted Critical
Publication of CN111065387B publication Critical patent/CN111065387B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Sustainable Development (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN201880058214.0A 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 Active CN111065387B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311033166.9A CN117018172A (zh) 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555479P 2017-09-07 2017-09-07
US62/555,479 2017-09-07
PCT/US2018/049309 WO2019050816A1 (en) 2017-09-07 2018-09-04 ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311033166.9A Division CN117018172A (zh) 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Publications (2)

Publication Number Publication Date
CN111065387A CN111065387A (zh) 2020-04-24
CN111065387B true CN111065387B (zh) 2023-08-25

Family

ID=65634538

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880058214.0A Active CN111065387B (zh) 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN202311033166.9A Pending CN117018172A (zh) 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311033166.9A Pending CN117018172A (zh) 2017-09-07 2018-09-04 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Country Status (10)

Country Link
US (3) US11389540B2 (enExample)
EP (1) EP3678652A4 (enExample)
JP (3) JP7218358B2 (enExample)
KR (1) KR102736151B1 (enExample)
CN (2) CN111065387B (enExample)
AU (2) AU2018328038B2 (enExample)
BR (1) BR112020004502A8 (enExample)
CA (1) CA3074711A1 (enExample)
MX (2) MX394767B (enExample)
WO (1) WO2019050816A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
BR112019017560A2 (pt) * 2017-02-24 2020-04-07 Merck Sharp & Dohme intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) * 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328040B2 (en) 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
BR112020004396A8 (pt) * 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
PT3678654T (pt) * 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
WO2019070994A1 (en) * 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
CA3089007A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
TW202011985A (zh) 2018-04-18 2020-04-01 韓商Ｓｋ生物科學股份有限公司 肺炎鏈球菌的莢膜多醣類以及其免疫原性接合體
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
KR102827174B1 (ko) 2018-04-30 2025-06-27 머크 샤프 앤드 돔 엘엘씨 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
JP7489324B2 (ja) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
CN113164581A (zh) 2018-09-23 2021-07-23 生物E有限公司 纯化的肺炎链球菌荚膜多糖
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847112A (en) * 1991-01-28 1998-12-08 Merck & Co., Inc. Process for making capsular polysaccharides from Streptococcus pneumoniae
CN101120013A (zh) * 2004-12-16 2008-02-06 食品和营养托浦研究所基金会 通过在非病原性、非侵入性革兰氏阳性菌中异源表达和分泌复合多糖而有效产生病原性革兰氏阳性菌荚膜多糖的新方法
CN102858365A (zh) * 2010-02-09 2013-01-02 默沙东公司 15价肺炎球菌多糖蛋白质缀合物疫苗组合物
CN103599529A (zh) * 2006-12-22 2014-02-26 惠氏公司 多价肺炎球菌多糖-蛋白质缀合物组合物

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
AU2003901717A0 (en) * 2003-04-10 2003-05-01 Western Sydney Area Health Service Identification of streptococcus pneumoniae serotypes
GB0313250D0 (en) 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
JP2008530037A (ja) 2005-02-11 2008-08-07 エース バイオサイエンシズ エー／エス 表面に位置したＳｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅのポリペプチド
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
AU2006234984B2 (en) 2005-04-08 2011-10-13 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
PL2878307T3 (pl) 2005-06-27 2020-01-31 Glaxosmithkline Biologicals S.A. Kompozycja immunogenna
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
JP5285431B2 (ja) 2005-12-28 2013-09-11 ザ ユーエイビー リサーチ ファウンデイション 肺炎球菌血清型
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
PT2074221E (pt) 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
WO2008148120A1 (en) 2007-05-29 2008-12-04 The Uab Research Foundation Pneumococcal serotype 6d
US8540955B2 (en) 2007-07-10 2013-09-24 Wyeth Llc Process for producing aluminum phosphate
EP2358754A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Ligands that bind il-13
KR101307703B1 (ko) 2008-12-18 2013-09-11 와이어쓰 엘엘씨 탄소를 사용하여 스트렙토코커스 뉴모니에 폴리사카라이드 분자량을 조절하는 방법
HUE037465T2 (hu) 2008-12-18 2018-09-28 Wyeth Llc Eljárás 19A szerotípusú streptococcus pneumoniae poliszacharidok molekulatömegének szabályozására
EP2391371B1 (en) 2009-01-27 2014-11-26 World Force Technologies, LLC A high molecular weight polysaccharide that binds and inhibits virus
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
US8748123B2 (en) 2009-12-15 2014-06-10 73100-Setenta e Tres Mil e Cem, Lda. Fucose-containing bacterial biopolymer
ES2614807T3 (es) 2010-06-04 2017-06-02 Wyeth Llc Formulaciones vacunales
US20130273098A1 (en) 2010-12-10 2013-10-17 Jeffrey T. Blue Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
ES2556951T3 (es) * 2011-05-27 2016-01-21 Universitätsklinikum Freiburg Polisacárido ramno del complejo clonal 17 de Enterococcus faecium y usos del mismo
EP2827899B1 (en) 2012-03-19 2015-08-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polysaccharide antigen-glycolipid conjugate vaccines
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075201A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CN104870463B (zh) 2012-12-20 2018-09-28 辉瑞公司 糖缀合方法
KR20220080201A (ko) 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CA2937190A1 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
BR112016015835B1 (pt) 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
SG11201700325SA (en) 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
KR102800419B1 (ko) * 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
HK1259103A1 (zh) 2015-11-17 2019-11-22 Pfizer Inc. 用於在细菌细胞培养物中生产多糖的培养基和发酵方法
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
KR102437120B1 (ko) 2016-08-05 2022-08-25 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
BR112019017560A2 (pt) 2017-02-24 2020-04-07 Merck Sharp & Dohme intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae
WO2018156465A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
WO2018156467A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
AU2018225083B2 (en) 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
US20200360500A1 (en) 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
AU2018328040B2 (en) 2017-09-07 2025-01-16 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
BR112020004396A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
KR20200077538A (ko) 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
KR102827174B1 (ko) 2018-04-30 2025-06-27 머크 샤프 앤드 돔 엘엘씨 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
JP7489324B2 (ja) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
WO2019236435A1 (en) 2018-06-07 2019-12-12 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
KR20220016964A (ko) 2019-06-05 2022-02-10 머크 샤프 앤드 돔 코포레이션 에스. 뉴모니아에 혈청형 29에 대해 보호하는 면역원성 조성물을 사용하여 환자를 치료하는 방법
BR112021024393A8 (pt) 2019-06-05 2023-01-31 Merck Sharp & Dohme Um conjugado de polissacarídeo-proteína pneumocócico de sorotipo 35b imunogênico e processo de conjugação para fabricar o mesmo

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847112A (en) * 1991-01-28 1998-12-08 Merck & Co., Inc. Process for making capsular polysaccharides from Streptococcus pneumoniae
CN101120013A (zh) * 2004-12-16 2008-02-06 食品和营养托浦研究所基金会 通过在非病原性、非侵入性革兰氏阳性菌中异源表达和分泌复合多糖而有效产生病原性革兰氏阳性菌荚膜多糖的新方法
CN103599529A (zh) * 2006-12-22 2014-02-26 惠氏公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN102858365A (zh) * 2010-02-09 2013-01-02 默沙东公司 15价肺炎球菌多糖蛋白质缀合物疫苗组合物

Also Published As

Publication number Publication date
RU2020112314A3 (enExample) 2022-03-23
BR112020004502A8 (pt) 2022-11-01
MX2022009928A (es) 2022-09-09
US11964023B2 (en) 2024-04-23
CA3074711A1 (en) 2019-03-14
EP3678652A4 (en) 2021-05-19
US20220323593A1 (en) 2022-10-13
JP2020533442A (ja) 2020-11-19
JP2023052619A (ja) 2023-04-11
MX394767B (es) 2025-03-24
CN111065387A (zh) 2020-04-24
AU2024201517A1 (en) 2024-03-28
BR112020004502A2 (pt) 2020-09-15
AU2018328038A1 (en) 2020-03-19
US20220323592A1 (en) 2022-10-13
CN117018172A (zh) 2023-11-10
KR20200051005A (ko) 2020-05-12
KR102736151B1 (ko) 2024-11-28
US20200282070A1 (en) 2020-09-10
JP7218358B2 (ja) 2023-02-06
JP2024133653A (ja) 2024-10-02
WO2019050816A1 (en) 2019-03-14
AU2018328038B2 (en) 2024-03-07
JP7519478B2 (ja) 2024-07-19
US11389540B2 (en) 2022-07-19
US11759523B2 (en) 2023-09-19
RU2020112314A (ru) 2021-10-07
MX2020002556A (es) 2020-07-13
EP3678652A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
CN111065387B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
JP7659672B2 (ja) 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN111093649B (zh) 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
KR102783492B1 (ko) 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
AU2024201518B2 (en) Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
RU2801304C2 (ru) Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель
RU2784449C2 (ru) Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель
RU2785429C2 (ru) Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220921

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant